Silk Road Medical's stock experienced a 4.1% move today, reaching a trading price of $13.08 per share. The company's latest announcement at the J.P. Morgan Healthcare Conference in January 2024, highlighted its innovative products such as Donna, TCAR, and CEA for patients.
In a statement regarding the company's outlook, management expressed confidence, stating, "We are optimistic about the future as we continue to develop and innovate our product offerings."
Furthermore, the company's Chief Financial Officer commented on the market outlook, saying, "We see great potential in the market as we strive to meet the increasing demand for our products."
For more detailed information, the company's full 8-K submission is available here.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Revenue (k) | $34,557 | $63,354 | $75,227 | $101,475 | $138,638 | $169,934 |
| Revenue Growth | n/a | 83.33% | 18.74% | 34.89% | 36.62% | 22.57% |
| Operating Margins | -62% | -44% | -56% | -47% | -38% | -34% |
| Net Margins | -109% | -83% | -63% | -49% | -40% | -33% |
| Net Income (k) | -$37,629 | -$52,415 | -$47,365 | -$49,811 | -$55,010 | -$55,346 |
| Net Interest Expense (k) | $4,361 | $4,952 | $4,411 | $2,518 | $5,098 | $6,869 |
| Depreciation & Amort. (k) | $517,000 | $712 | $789 | $1,032 | $2,127 | $2,702 |
| Free Cash Flow (k) | -$23,971 | -$30,145 | -$42,910 | -$43,693 | -$37,586 | -$28,906 |
| Capital Expenditures | $2,276 | $535 | $842 | $4,758 | $5,005 | $2,621 |
| Current Ratio | 3.6 | 6.64 | 8.86 | 5.49 | 10.41 | 10.03 |
